Pharma Focus Asia

Argenx and Zai Lab Announces Biologics Licence Application (BLA) for VYVGART® (efgartigimod alfa injection)

Saturday, July 01, 2023

Argenx and Zai Lab have announced that the Biologics Licence Application (BLA) for VYVGART® (efgartigimod alfa injection) has been approved by China's National Medical Products Administration (NMPA).

VYVGART is a first-in-class neonatal Fc receptor (FcRn) antagonist and is intended to be used as an add-on therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

VYVGART is a human IgG1 antibody fragment that targets the neonatal Fc receptor, resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker for the treatment of gMG in the United States, European Union, and China.

This approval marks an important milestone in the treatment of gMG in China. Clinical studies have shown that efgartigimod has remarkable onset of action, efficacy, and safety profiles, leading to improvements in muscle strength and quality of life for patients. 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024